266 Appendices 51. M.D. Zwan: Visualizing Alzheimer’s disease pathology. Implementation of amyloid PET in clinical practice (03-03-2016) 52. E. Louwersheimer: Alzheimer’s disease: from phenotype to genotype (21-06-2016) 53. W.A. Krudop: The frontal lobe syndrome: a neuropsychiatric challenge (23-09- 2016) 54. E.G.B. Vijverberg: The neuropsychiatry of behavioural variant frontotemporal dementia and primary psychiatric disorders: similarities and dissimilarities (22-09- 2017) 55. F.T. Gossink: Late Onset Behavioural Changes differentiating between bvFTD and psychiatric disorders in clinical practice (20-04-2018) 56. M.A. Engels: Neurophysiology of dementia (18-05-2018) 57. S.C.J. Verfaillie: Neuroimaging in subjective cognitive decline: Incipient Alzheimer’s disease unmasked (12-09-2018) 58. M. ten Kate: Neuroimaging in predementia Alzheimer’s disease (13-09-2018) 59. H.F.M. Rhodius-Meester: Optimizing use of diagnostic tests in memory clinics; the next step (24-09-2018) 60. E.A.J. Willemse: Optimising biomarkers in cerebrospinal fluid. How laboratory reproducibility improves the diagnosis of Alzheimer’s disease (18-10-2018) 61. E. Konijnenberg: Early amyloid pathology – Identical twins, two of a kind? (25- 06-2019) 62. A.E. Leeuwis: Connecting heart and brain; Vascular determinants of cognitive impairment and depressive symptoms (02-07-2019) 63. J. den Haan: Imaging the retina in Alzheimer’s disease (12-09-2019) 64. A.C. van Loenhoud: Cognitive reserve in Alzheimer’s disease. A perspective on the flourishing and withering of the brain (18-09-2019) 65. R.J. Jutten: Capturing changes in cognition; refining the measurement of clinical progression in Alzheimer’s disease (20-09-2019) 66. N. Legdeur: Determinants of cognitive impairment in the oldest-old (08-10-2019) 67. R. Slot: Subjective cognitive decline – predictive value of biomarkers in the context of preclinical Alzheimer’s disease (14-11-2019) 68. N. Scheltens: Understanding heterogeneity in Alzheimer’s disease – a data driven approach (17-12-2019) 69. L. Vermunt: Secondary prevention for Alzheimer’s Disease – timing, selection, and endpoint of clinical trials (13-03-2020) 70. L.M.P. Wesselman: Lifestyle and brain health – exploring possibilities of an online intervention in non-demented elderly (01-04-2020) 71. I.S. van Maurik: Interpreting biomarker results in patients with mild cognitive impairment to estimate prognosis and optimize decision making (12-05-2020) (Cum Laude) 72. E. Dicks: Grey matter covariance networks in Alzheimer’s disease: Edging towards a better understanding of disease progression (09-09-2020) 73. J.J. van der Zande: A sharper image of dementia with Lewy bodies: the role of imaging and neurophysiology in DLB, and the influence of concomitant Alzheimer’s disease pathology (21-09-2020)
RkJQdWJsaXNoZXIy MjY0ODMw